Give information on adverse events and possible interactionsa, b
| | | |
0.022
|
Yes
|
30
|
53
|
21
|
44
|
51
|
48
| |
Sometimes
|
26
|
46
|
18
|
38
|
44
|
42
| |
No
|
1
|
2
|
8
|
17
|
9
|
9
| |
Ask customers about PD use when selling DSa, b
| | | |
0.021
|
Always
|
15
|
26
|
11
|
23
|
26
|
25
| |
Sometimesc
|
41
|
72
|
28
|
58
|
69
|
66
| |
Depending on the customers’ health
|
9
|
16
|
0
|
0
|
9
|
9
| |
Depending on the type of DS
|
32
|
56
|
28
|
58
|
60
|
57
| |
Never
|
1
|
2
|
8
|
17
|
9
|
8
| |
Ask customers about DS use when dispensing PDa, d
| | | |
0.002
|
Always
|
0
|
0
|
2
|
4
|
2
|
2
| |
Sometimes
|
32
|
56
|
12
|
25
|
44
|
42
| |
Never
|
24
|
42
|
33
|
69
|
57
|
54
| |
Routinely check for interactions between DS and PDe, f
| | | |
0.409
|
Always
|
7
|
12
|
10
|
21
|
17
|
16
| |
Sometimesf
|
40
|
70
|
28
|
58
|
68
|
65
| |
In certain patients groups
|
12
|
21
|
3
|
6
|
15
|
14
| |
For certain DS
|
34
|
60
|
18
|
38
|
52
|
50
| |
For certain PD
|
16
|
28
|
17
|
35
|
33
|
31
| |
Never
|
10
|
18
|
7
|
15
|
17
|
16
| |